Make a ppt of 25 slides on topic hypertensive disorders of pregnancy mainly pre-eclampsia definitions etiopathology in detail prevention of pre-eclampsia predictive factors of pre-eclampsia investigations and it's management from standard text books
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Running Command
Writing File
Running Command
Running Command
Running Command
Your 25-slide presentation is ready:
Hypertensive Disorders Pregnancy
Presentation · PPTX
What's Inside (All 25 Slides)
The deck uses a professional deep navy / crimson / teal color scheme with section dividers and formatted tables.
| # | Slide | Content |
|---|---|---|
| 1 | Title Slide | Full topic, subtopics, textbook sources listed |
| 2 | Overview & Epidemiology | 5–7% prevalence, spectrum of HDP, mortality burden |
| 3 | Section Divider | Definitions & Classification |
| 4 | Definitions | Gestational HTN, Pre-eclampsia (ACOG 2013 criteria), Eclampsia |
| 5 | Severe Features & HELLP | All 7 severe features; HELLP triad with lab thresholds |
| 6 | Section Divider | Etiopathology |
| 7 | Role of the Placenta | Central role; ischemia hypothesis; pathological findings |
| 8 | Abnormal Vascular Remodeling | Spiral artery invasion failure; pseudovasculogenesis defect; HIF-1 |
| 9 | Angiogenic Imbalance | sFlt-1, sEng, PlGF, VEGF; TXA2/PGI2 imbalance; endothelin-1; nitric oxide |
| 10 | Risk Factors | High-risk (nulliparity, prior PE, multifetal) and moderate-risk factors |
| 11 | Multisystem Pathophysiology | Two-column: organ systems affected + hemodynamic profile |
| 12 | Section Divider | Predictive Factors |
| 13 | Predictors: Clinical & Biochemical | FMF combined screen; Doppler; PP-13; sFlt-1/PlGF ratio |
| 14 | Biomarkers Table | 7-row table: biomarker, timing, significance |
| 15 | Section Divider | Prevention |
| 16 | Prevention Strategies | Low-dose aspirin (mechanism + dosing); calcium; Vit C/E; heparin |
| 17 | Aspirin: The Evidence | ASPRE Trial (62% reduction pre-term PE); bedtime dosing; multifetal considerations |
| 18 | Section Divider | Investigations |
| 19 | Investigations | FBC, urinalysis, LFTs, creatinine, LDH, coagulation; sFlt-1/PlGF ratio |
| 20 | Fetal Assessment & Imaging | CTG, BPP, growth scan; uterine + umbilical artery Doppler; CT/MRI brain |
| 21 | Section Divider | Management |
| 22 | Management Principles & Timing | Delivery thresholds by gestational age; BP targets; indications for urgent delivery |
| 23 | Antihypertensive Drugs Table | Labetalol, hydralazine, nifedipine, methyldopa, ACEi (contraindicated) |
| 24 | Magnesium Sulfate | Magpie Trial; Pritchard regimen; toxicity monitoring; calcium gluconate antidote |
| 25 | Summary & Long-term Implications | Key takeaways; CVD risk post-PE; pregnancy as cardiovascular stress test |
Sources cited throughout: Brenner & Rector's The Kidney (10e), Creasy & Resnik's Maternal-Fetal Medicine (8e), Morgan & Mikhail's Clinical Anesthesiology (7e), ACOG Practice Bulletins, and the Magpie Trial.
This is a shared conversation. Sign in to Orris to start your own chat.